TrialCompass™ TCL
Back to trials
RecruitingPriority 4 · Lower priorityNCT03932279

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 1 location in the United States.

Who can join (key eligibility)

  • Age 18 Years to 89 Years years
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is CTCL?

Plain-language overview of CTCL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

NCT03932279

Status: Recruiting | Priority: Lower

Plain-language summary

This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial is available at 1 location in the United States.

Who can join

  • Age 18 Years to 89 Years years
  • See full trial listing for complete eligibility

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 300 patients

Primary endpoint: Bacterial diversity index

Ages: 18 Years to 89 Years

Start date: 2019-01-30 | Est. completion: 2028-08-31

Locations

1 US sites · 1 total

Illinois

Contact

Dermatology CTU | NUderm-research@northwestern.edu | 312-503-5944

Sponsor: Northwestern University (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT03932279

Prepared using TrialCompass (trialcompass.com) on August 18, 2026. For informational purposes only. Always discuss with your healthcare team.